Lebrikizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lebrikizumab
Accession Number
DB11914  (DB05962)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
TNX-650
Categories
UNII
U9JLP7V031
CAS number
953400-68-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Anti-IL-13 humanized monoclonal antibody Lebrikizumab binds to and blocks the activity of IL-13, which may result in the inhibition of Hodkin lympoma cell proliferation. IL-13 cytokine, an important mediator in allergic inflammation, may be an autocrine growth factor for Hodgkin lymphoma cells.

TargetActionsOrganism
UInterleukin-13Not AvailableHuman
UIL13 proteinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lebrikizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Lebrikizumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lebrikizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Lebrikizumab.
AducanumabThe risk or severity of adverse effects can be increased when Lebrikizumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Lebrikizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lebrikizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Lebrikizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Lebrikizumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Lebrikizumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911256
Wikipedia
Lebrikizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers2
1, 2Unknown StatusTreatmentLymphoma, Hodgkins1
2CompletedTreatmentAsthma Bronchial5
2CompletedTreatmentAsthma, Allergic1
2CompletedTreatmentAtopic Dermatitis (AD)2
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2RecruitingTreatmentAtopic Dermatitis (AD)1
2TerminatedTreatmentAsthma Bronchial1
3CompletedTreatmentAsthma Bronchial4
3WithdrawnTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Interleukin-13 receptor binding
Specific Function
Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
Gene Name
IL13
Uniprot ID
P35225
Uniprot Name
Interleukin-13
Molecular Weight
15815.585 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
IL13
Uniprot ID
Q4VB53
Uniprot Name
IL13 protein
Molecular Weight
9044.53 Da

Drug created on October 20, 2016 15:00 / Updated on November 02, 2018 07:17